Every year, more than 3,000 scientific abstracts are accepted for oral and poster presentation at the Society's annual meeting.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
Early registration is now open. Hear top experts in hematologic malignancies discuss the latest developments in clinical care.
Register for ASH's upcoming webinar, Chimeric T-Cell Antigen Receptor Therapy in Leukemia and Lymphoma, taking place April 22.
Obtain CME credit and a certificate of attendance for the 56th ASH Annual Meeting by April 17, 2015.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to medical research.
Search a database of practicing hematologists in your area.
Help move hematology forward by supporting research, career development, and quality care and education programs.
Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.
Last night the Senate
passed legislation permanently repealing the Sustainable Growth Rate, a
flawed formula mandating annual reductions in Medicare physician payments, and
replacing it with a 0.5 percent annual physician pay increase for the next five
The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the latest recipients of the ASH Bridge Grant Awards. These one-year, $150,000 awards are designed to provide critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the NIH due to severe funding reductions. The 11 ASH Bridge Grant recipients announced today join 51 hematologists that have received funding since ASH committed $9 million in Society funds to create the program in 2012.
New research published online today in Blood, the Journal of the American Society of Hematology, reports that children with “bubble boy disease” who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor. The research is the first to compare outcomes among children with the rare immune disorder – also known as X-linked severe combined immunodeficiency (SCID-X1) – receiving the two therapeutic approaches.
A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma.
On April 16, President Obama signed the Medicare Access and CHIP Reauthorization Act of 2015
(MACRA) into law. Follow the link above to read a detailed report of what the legislation means for hematologists.
The NIH has released a request for information soliciting input on the possible development of new policies and strategies to improve the impact and sustainability of its funded biomedical research enterprise. ASH members are encouraged to submit comments in response to this request.
On March 30, the
Centers for Medicare & Medicaid Services (CMS) issued two documents on Medicare
Part B and Part D payment for biosimilars that are relevant to hematology. On March 6, 2015, the FDA)approved filgrastim-sndz (ZARXIO Injection, Sandoz Inc.),
as a biosimilar to U.S.-licensed Neupogen, which is important to hematologic
therapy. Some of the most important
regimens for the treatment of patients with
hematologic disorders are biologic, so the release of this information is helpful for the field.
The Institute of Medicine National Cancer Policy Forum (IOM NCPF) has released a summary report on a workshop it hosted on November 10, 2014, titled "Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies." This report highlights the numerous challenges raised by workshop participants on the development of biomarker tests, implementation of cancer therapies into the clinic, clinical trial structure and reimbursement issues related to molecular profiling tests.
Dr. Levine and Dr. Gilliland discuss developments that have come about in the past 10 years regarding JAK2 V617F after Dr. Dameshek's study of the classification of different MPNs in 2005.
ASH's Visitor Training Program grant helped bring Dr. Tamunomieibi Wakama to train in diagnostic hematopathology at Roswell Park Cancer Institute (RPCI).
Dr. Verstovsek discusses the benefits of treatment with JAK Inhibitors through the study of three clinical trials.
New Drugs to Match My New Genes? A Look Back at the 56th ASH Annual Meeting
For us hematologists, the first full weekend in December is typically blacked out in our calendars. During this sacred time, ASH hosts its annual meeting for anyone interested in the basic science, clinical
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology